

## SEQUENCE LISTING

110> Lee et al.

```
<120> Inhibiting formation of Artherosclerotic Lesions
<130> 21509-042
<140> 09/503,596
<141> 2000-02-11
<150> 60/119,880
<151> 1999-02-12
<160> 8
<170> PatentIn Ver. 2.0
<210> 1
<211> 614
<212> DNA
<213> Mus musculus
<400> 1
cctttctcac ctggaagaca gctcctcctc gaaggtttac aaaatgtgtg atgcctttgt 60
gggaacctgg aagcttgtct ccagtgaaaa cttcgatgat tacatgaaag aagtgggagt 120
gggctttgcc acaaggaaag tggcaggcat ggccaagccc aacatgatca tcagcgtaaa 180
tggggatttg gtcaccatcc ggtcagagag tacttttaaa aacaccgaga tttccttcaa 240
actgggcgtg gaattcgatg aaatcaccgc agacgacagg aaggtgaaga gcatcataac 300
cctagatggc ggggccctgg tgcaggtgca gaagtgggat ggaaagtcga ccacaataaa 360
gagaaaacga gatggtgaca agctggtggt ggaatgtgtt atgaaaggcg tgacttccac 420
aagagtttat gaaagggcat gagccaaagg aagaggcctg gatggaaatt tgcatcaaac 480
actacaatag tcagtcggat ttattgtttt ttttaaagat atgattttcc actaataagc 540
aagcaattaa ttttttctga agatgcattt tattggatat ggttatgttg attaaataaa 600
                                                                   614
acctttttag actt
<210> 2
<211> 634
<212> DNA
<213> Homo sapiens
<400> 2
ggaattccag gagggtgcag cttccttctc accttgaaga ataatcctag aaaactcaca 60
aaatgtgtga tgcttttgta ggtacctgga aacttgtctc cagtgaaaac tttgatgatt 120
atatgaaaga agtaggagtg ggctttgcca ccaggaaagt ggctggcatg gccaaaccta 180
acatgatcat cagtgtgaat ggggatgtga tcaccattaa atctgaaagt acctttaaaa 240
atactgagat ttccttcata ctgggccagg aatttgacga agtcactgca gatgacagga 300
aagtcaagag caccataacc ttagatgggg gtgtcctggt acatgtgcag aaatgggatg 360
```

```
gaaaatcaac caccataaag agaaaacgag aggatgataa actggtggtg gaatgcgtca 420
tgaaaggcgt cacttccacg agagtttatg agagagcata agccaaggga cgttgacctg 480
gactgaagtt cgcattgaac tctacaacat tctgtgggat atattgttca aaaagatatt 540
gttgttttcc ctgatttagc aagcaagtaa ttttctccca agctgatttt attcaatatg 600
gttacgttgg ttaaataact ttttttagat ttag
<210> 3
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Antigenic fragment of AFABP.
<400> 3
Asp Lys Leu Val Val Glu Cys Val Met Lys Gly Val Thr
                                      10
<210> 4
<211> 132
<212> PRT
<213> Homo sapiens
<400> 4
Met Cys Asp Ala Phe Val Gly Thr Trp Lys Leu Val Ser Ser Glu Asn
  1
                  5
                                      10
                                                          15
Phe Asp Asp Tyr Met Lys Glu Val Gly Val Gly Phe Ala Thr Arg Lys
             20
                                  25
                                                      30
Val Ala Gly Met Ala Lys Pro Asn Met Ile Ile Ser Val Asn Gly Asp
         35
                              40
                                                  45
Val Ile Thr Ile Lys Ser Glu Ser Thr Phe Lys Asn Thr Glu Ile Ser
     50
                         55
Phe Ile Leu Gly Gln Glu Phe Asp Glu Val Thr Ala Asp Asp Arg Lys
 65
                     70
                                          75
Val Lys Ser Thr Ile Thr Leu Asp Gly Gly Val Leu Val His Val Gln
                 85
                                      90
Lys Trp Asp Gly Lys Ser Thr Thr Ile Lys Arg Lys Arg Glu Asp Asp
            100
                                 105
```

634

RECEIVED

FEB 20 2001

TECH CENTER HERE TO

2

120

115

Lys Leu Val Val Glu Cys Val Met Lys Gly Val Thr Ser Thr Arg Val

125

l

```
Tyr Glu Arg Ala
    130
<210> 5
<211> 132
<212> PRT
<213> Mus musculus
<400> 5
Met Cys Asp Ala Phe Val Gly Thr Trp Lys Leu Val Ser Ser Glu Asn
  1
                  5
                                      10
                                                           15
Phe Asp Asp Tyr Met Lys Glu Val Gly Val Gly Phe Ala Thr Arg Lys
             20
Val Ala Gly Met Ala Lys Pro Asn Met Ile Ile Ser Val Asn Gly Asp
         35
                              40
                                                   45
Leu Val Thr Ile Arg Ser Glu Ser Thr Phe Lys Asn Thr Glu Ile Ser
     50
                          55
                                              60
Phe Lys Leu Gly Val Glu Phe Asp Glu Ile Thr Ala Asp Asp Arg Lys
 65
                      70
                                          75
Val Lys Ser Ile Ile Thr Leu Asp Gly Gly Ala Leu Val Gln Val Gln
                 85
                                      90
                                                           95
Lys Trp Asp Gly Lys Ser Thr Thr Ile Lys Arg Lys Arg Asp Gly Asp
            100
                                 105
                                                      110
Lys Leu Val Val Glu Cys Val Met Lys Gly Val Thr Ser Thr Arg Val
        115
                             120
Tyr Glu Arg Ala
    130
<210> 6
```

<211> 351 <212> DNA <213> Mus musculus

<400> 6

cctttctcac ctggaagaca gctcctcctc gaaggtttac aaaatgtgtg atgcctttgt 60 gggaacctgg aagcttgtct ccagtgaaaa cttcgatgat tacatgaaag aagtgggagt 120 gggctttgcc acaaggaaag tggcaggcat ggccaagccc aacatgatca tcagcgtaaa 180

tggggatttg gtcaccatcc ggtcagagag tacttttaaa aacaccgaga tttccttcaa 240 actgggcgtg gaattcgatg aaatcaccgc agacgacagg aaggtgaaga gcatcataac 300 cctagatggc ggggccctgg tgcaggtgca gaagtgggat ggaaagtcga c <210> 7 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Linker sequence between light and heavy chain variable regions in AFABP specific antibodies <400> 7 Gly Ser Ser Ser <210> 8 <211> 518 <212> DNA <213> Mus musculus <400> 8 gaattccagc aggaatcagg tagctggaga atcgcacaga gccatgcgat tcttggcaag 60 ccatgcgaca aaggcagaaa tgcacatttc acccagagag aagggattga tgtcagcagg 120 aagtcaccac ccagagagca aatggagttc ccagatgcct gacatttgcc ttcttactgg 180 atcagagttc actagtggaa gtgtcacagc ccaaacactc ccccaaagct cagcccttcc 240 ttgccttgta acaatcaagc cgctcctgga tgaactgctc cgccctctgt ctctttggca 300

gggttggage ceaetgtgge etgagegaet tetatggete cettttetgt gatttteatg 360 gtttetgage tetttteece egetttatga ttttetett ttgtetetet ettgetaaac 420 eteettegta tatatgeeet eteaggttte atttetgaat eatetaetgt gaactattee 480

cattgtttgc cagaagcccc ctggttcttc cttctaga

518